Browse drugs

…dian 9.2%). One biopsy lacked B cells; the patient had received rituximab 9 months previously. In pre- and post- treatment samples infilt…

…11), antimalarials (n= 55), tacrolimus (n= 27), everolimus (1), belimumab (BLM) (19) and anifrolumab (1). After a follow-up of 59.7±46 mo…

…omitant immunosuppressive biologics in LN patients treated with voclosporin. This is notable given the unique and possibly synergistic effe…

…ected. Forty-eight patients received B-cell targeted therapies (belimumab 40=; rituximab n=8). For these, treatment duration, reasons for…

…3), organ damage (SLICC/ACR Damage Index) (SDI), treatments and prednisone dosages for every visit were collected.We compared patients nev…

…b in 25, belimumab in 16, obinutuzumab in 2, voclosporin in 21, tacrolimus in 6, cyclosporin-A in 4 and azathioprine in 3 patients. Six pa…

…h results from pivotal trials (TULIP-1 and TULIP-2), supporting anifrolumab as an effective therapeutic option for patients with SLE, altho…

…frolumab treatmentConclusions In this real-world Danish cohort, anifrolumab produced substantial and sustained reductions in disease activi…

…sant; 3/5 rituximab and 4/5 belimumab. Concomitant therapy: 5/5 hydroxychloroquine, 4/5 MMF/Na, 5/5 prednisone (mean baseline dose 15 mg/day (10-1…

…s received BLM after bDMARD. The main bDMARD use before BLM was rituximab in the 85.3% of patients. Baseline characteristics are summariz…

…prine (16%), methotrexate (9%), and mycophenolate mofetil (9%). Rituximab was used in 7% of severe or treatment-resistant patients.Conclu…

…pressant, 36 (13.3%) Belimumab, 14 (5.2%) Anifrolumab, 4 (1.5%) Rituximab, and only 46 (17%) glucocorticoids, of whom 80.4% were on doses…